Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer-Reference-Cited by-同舟云学术

Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer

Published:2019-04-10 Issue:4 Volume:14 Page:e0214610
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

O’Flaherty Linda,Shnyder Steven D.,Cooper Patricia A.,Cross Stephen J.^ORCID,Wakefield James G.,Pardo Olivier E.,Seckl Michael J.,Tavaré Jeremy M.^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. GSK3 takes centre stage more than 20 years after its discovery;S Frame;Biochem J,2001

2. GSK-3: tricks of the trade for a multi-tasking kinase;BW Doble;Journal of cell science,2003

3. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics;RS Jope;Neurochem Res,2007

4. What Are the bona fide GSK3 Substrates?;C Sutherland;Int J Alzheimers Dis,2011

5. Multifaceted Roles of GSK-3 and Wnt/beta-catenin in Hematopoiesis and Leukemogeneis: Opportunities for Therapeutic Intervention;JA McCubrey;Leukemia,2013

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Modulation of the Cytosolic Oscillator Affects Glioblastoma Cell Biology;Cellular and Molecular Neurobiology;2024-06-22

2. In vitro evaluation of the effects of potential GSK-3β inhibitors terbutaline and orciprenaline;Trakya University Journal of Natural Sciences;2024-04-15

3. GSK3β phosphorylates Six1 transcription factor and regulates its APC/CCdh1 mediated proteosomal degradation;Cellular Signalling;2024-03

4. Pharmacological modulation of the cytosolic oscillator affects glioblastoma cell biology;2024-02-26

5. Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma;Cancer Science;2024-02-06